中文

603456 Revenue Breakdown

Period 2026-06-30 ・ Reported 2026-08-04

603456 reported revenue of ¥2.58B for the period ended 2026-06-30, -10.3% year on year. Net income was ¥0.38B, a 14.8% net margin on a 36.9% gross margin. The largest revenue line is 新药定制研发和生产服务(CDMO) at 77% of the total. Free cash flow for the period was ¥0.34B.

ItemAmountY/Y
Revenue¥2.58B-10.3%
Gross profit¥0.95B
Operating income¥0.49B
Net income¥0.38B-27.7%
Gross margin36.9%Net margin 14.8%
Revenue Q/Q+14.5%

Revenue Segments

SegmentRevenueShare
新药定制研发和生产服务(CDMO)¥1.97B76.6%
特色原料药及中间体¥0.51B20.0%
其他¥0.09B3.4%

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥1.63B63.1%
R&D¥0.13B5.0%
SG&A¥0.26B10.1%
Tax & other¥0.11B4.1%

Balance sheet & cash flow

ItemAmount
Operating cash flow¥0.42B
Capital expenditure¥0.08B
Free cash flow¥0.34B
Cash conversion (OCF / net income)145%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

万科A中兴通讯TCL科技中联重科申万宏源东方盛虹美的集团潍柴动力藏格矿业徐工机械云南白药泸州老窖

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies